Par’s Megace Extra Strength May Launch With Contract Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will likely seek an exclusive sales force of 40 to 80 reps for the reformulated version of Bristol’s megestrol oral suspension product. Par expects to launch in mid-2005; its 505(b)(2) NDA has a user fee date of April 29.
You may also be interested in...
Par's Megace ES Clears FDA; Company Will Target Generic Megestrol Users
Concentrated version of the appetite stimulant megestrol acetate oral suspension will launch the week of July 11 through Par's 59-rep sales force. The company expects to convert half the $60 mil. generic market for megestrol acetate oral suspension to Megace ES by the end of 2006.
Par's Megace ES Clears FDA; Company Will Target Generic Megestrol Users
Concentrated version of the appetite stimulant megestrol acetate oral suspension will launch the week of July 11 through Par's 59-rep sales force. The company expects to convert half the $60 mil. generic market for megestrol acetate oral suspension to Megace ES by the end of 2006.
Par Planning Megace ES Launch In Summer 2005 With In-House Sales Force
Par is looking for a second product to detail with the 50-60 person force it is building for extra strength Megace. The company hopes to get an "approvable" letter for the product in April and begin detailing in July.